Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 184

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 184
---
 

        Available-for-sale debt securities maturing:
         
        Amortized Cost

        Estimated Fair Value

        In one year or less
         
        $
        19,420

        $
        19,424

        Total available-for-sale debt securities
         
        $
        19,420

        $
        19,424

       Marketable Equity SecuritiesMarketable equity securities are reported at fair value with unrealized gains and losses related to mark-to-market adjustments included in income. Lineage’s marketable equity securities have consisted of shares of common stock of OCX and of HBL. All share prices are determined based on the closing price of OCX and HBL common stock on the last trading day of the applicable quarter.  Lineage has not owned any shares of OCX since June 30, 2024.  The following table represents the realized and unrealized loss on marketable equity securities for the periods presented (in thousands): 

        Year Ended December 31,

        2024

        2023

        Loss on marketable equity securities, net
         
        $
        (8
        )
         
        $
        (176
        )

        Less: Loss recognized in earnings on marketable equity securities sold

        4

        23

        Unrealized loss recognized on marketable equity securities held at    end of period, net
         
        $
        (4
        )
         
        $
        (153
        )

115

5. Property and Equipment, NetAt December 31, 2024 and 2023, property and equipment, net was comprised of the following (in thousands): 

        December 31, 2024

        December 31, 2023

        Equipment, furniture and fixtures
         
        $
        4,131

        $
        3,614

        Leasehold improvements

        2,300

        2,313

        Right-of-use assets - finance lease

        204

        198

        Accumulated depreciation and amortization

        (4,384
        )

        (3,880
        )

        Property and equipment, net
         
        $
        2,251

        $
        2,245

       Depreciation and amortization expense was $587,000 and $562,000 for the years ended December 31, 2024 and 2023, respectively